Pediatric
Johnson & Johnson Seeks U.S. FDA Approval for First Pediatric Indications for TREMFYA®
Johnson & Johnson
PR-12-24-NI-126Dec 03, 2024
Large Molecule
Johnson & Johnson Submits Applications Seeking Approval as Subcutaneous Monotherapy for High-Risk moldering Multiple Myeloma
Johnson & Johnson
PR-10-24-NI-88Nov 08, 2024
Clinical Trials
TREMFYA is the first and only IL-23 inhibitor to demonstrate robust results with regimen in both induction and maintenance
Johnson & Johnson
PR-10-24-NI-64Oct 28, 2024
Clinical Trail
TALVEY and DARZALEX FASPRO shows deep and durable responses in patients with relapsed or refractory multiple myeloma
Johnson & Johnson
PR-09-24-NI-21Sep 27, 2024
Clinical Trails
TALVEY and TECVAYLI suggests high response rates in triple-class refractory patients with relapsed or refractory multiple myeloma
Johnson & Johnson
PR-09-24-NI-20Sep 27, 2024
COVID-19 Trials
Johnson & Johnson Initiates Pivotal Global Phase 3 Clinical Trial of Janssen’s COVID-19 Vaccine Candidate
Johnson & Johnson
PR-M09-20-27Sep 24, 2020
Vaccine
European Commission Concludes Further Talks to Secure J&J COVID-19 Vaccine
Johnson & Johnson
PR-M08-20-NI-24Aug 14, 2020
COVID-19 Vaccine
Johnson & Johnson Announces Agreement with U.S. Government for 100 Million Doses of Investigational COVID-19 Vaccine
Janssen Pharmaceutical Companies
PR-M08-20-NI-11-1359Aug 06, 2020
HIV Prevention
Johnson & Johnson and Its Partners Mark a Milestone in the Quest for a Global Preventive HIV Vaccine with the Imbokodo Study
Johnson & Johnson
PR-M07-20-NI-026Jul 16, 2020
COVID-19 Vaccine Manufacturing
Emergent BioSolutions Signs Five-Year Agreement for Large-Scale Drug Substance Manufacturing for Johnson & Johnson’s Lead COVID-19 Vaccine Candidate
Emergent Biosolutions
PR-M07-20-NI-007Jul 07, 2020
COVID-19 Vaccine
Catalent Signs Agreement with Johnson & Johnson to be U.S. Manufacturing Partner for Lead COVID-19 Vaccine Candidate
Catalent
PR-M04-20-NI-044-1583Apr 30, 2020
Vaccine
Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19
Johnson & Johnson
PR-M03-20-NI-045Mar 31, 2020
Coronavirus
J&J Cites Lack of Evidence for HIV Treatment Against COVID-19
Johnson & Johnson
PR-M03-20-NI-026Mar 17, 2020
Collaboration
Johnson & Johnson Announces Collaboration with U.S. Department of Health & Human Services to Accelerate Development of a Potential Novel Coronavirus Vaccine
Johnson & Johnson
PR-M02-20-NI-017Feb 14, 2020
Depression
Trump Urges VA to Use Spravato
Nice Insight
PAO-M00-19-NI-007Sep 04, 2019
Opioid Crisis
J&J Awaits Judge’s Decision in Lawsuit Filed by Oklahoma Over the Opioid Crisis
Nice Insight
PAO-M07-19-NI-021Jul 22, 2019
FDA Approval
FDA Grants Additional Myeloma Approval to J&J’s Darzalex
Emilie Branch
Pharma's Almanac
PAO-M07-19-NI-014Jul 10, 2019
Opioid Crisis
Oklahoma vs. Johnson & Johnson Opioid Crisis Trial
Nice Insight
PAO-M06-19-NI-006Jun 13, 2019
Oncology
FDA Will Use Real-Time Oncology Review for Prostate Cancer Drug
Pharma's Almanac
PAO-M05-19-NI-012May 10, 2019
Diabetes
J&J Believes its Diabetes Drug Invokana Is A Game Changer
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-M04-19-NI-021Apr 18, 2019